View Older Stories
-
Abbott Labs (ABT) PT Lowered to $110; Bernstein: 'Good entry point, or value trap?'
-
Abbott Labs (ABT) PT Lowered to $115 at Piper Sandler After a 'Disappointing Q1'
-
Abbott Labs (ABT) PT Lowered to $115 at TD Cowen
-
Abbott Labs (ABT) PT Lowered to $130 at RBC Capital
-
Abbott Labs (ABT) PT Lowered to $110 at Bernstein SocGen Group
-
Abbott Labs (ABT) PT Lowered to $120 at Stifel Following Q1 Results
-
Abbott Labs (ABT) PT Lowered to $115 at Oppenheimer
-
Abbott Labs (ABT) PT Lowered to $120 at Benchmark on Updated Guidance
-
Abbott Labs (ABT) PT Lowered to $120 at BofA Securities
-
Abbott (ABT) 51K contracts, compared to its 90-day average of 15K contracts, share price down 5.3%
-
Leerink Partners on Abbott Labs (ABT): U.S. MedTech softness could be viewed unfavorably
-
Abbott shares dip on soft current-quarter guide; Q1 results in line
-
Abbott (ABT) Reports In-Line Q1 EPS; offers guidance
-
Abbott (ABT) call put ratio 1.5 calls to 1 put into quarter results
-
TD Cowen: 'Abbott Labs (ABT) Stock Reaction Overdone'
-
Abbott Owes $17 Million Punitive Damages In Baby-formula Trial - Bloomberg
-
Abbott integrates precision oncology tests with Flatiron's OncoEMR platform
-
UBS Reiterates Buy Rating on Abbott Labs (ABT) on DD Medical Device Growth Sustainability
-
Abbott Labs (ABT) Reiterated at Buy by Benchmark After FreeDM Trial Results
-
Piper Sandler's Key Takeaways From CRT 2026
-
Piper Sandler: 'When Will Things Turn in Med Tech and What Names to Own Now?'
-
Exact Sciences shareholders approve $105 per share Abbott acquisition
-
Abbott (ABT) Declares $0.63 Quarterly Dividend; 2.3% Yield
-
Abbott presents positive 12-month data on atrial fibrillation devices
-
Abbott Labs (ABT) PT Lowered to $119 at Leerink Partners
-
Increasing unusual put option volume: TRIP ABT GTM SAP URI COPX KOS XRX SYK INTU
-
Freedom Capital Markets Upgrades Abbott Labs (ABT) to Buy
-
Increasing unusual put option volume: KDP HYMC GOSS FE TSCO HUM LRN APH AQST ABT IBRX
-
Increasing unusual put option volume: KDP VFC GOSS UL AR CPNG EQNR SYY JETS UUP XRX ABT NOC GLW
-
UBS Reiterates Buy Rating on Abbott Labs (ABT), Says Sales Growth to Drive Shares
-
Abbott Labs (ABT) PT Lowered to $125 at Bernstein SocGen Group
-
Abbott Labs (ABT) PT Lowered to $137 at TD Cowen
-
Benchmark Reiterates Buy Rating on Abbott Labs (ABT): Annual Estimates Unchanged
-
Abbott Labs (ABT) PT Lowered at RBC Capital Amid 'Challenging Year-End'
-
Abbott Labs (ABT) PT Lowered to $135 at Piper Sandler After a 'Disappointing Q4'
-
Abbott Labs (ABT) PT Lowered to $132 at Oppenheimer
-
Abbott Labs (ABT) PT Lowered to $122 at Wells Fargo
-
Abbott Labs (ABT) PT Lowered to $130 at Raymond James
-
Abbott Labs (ABT) PT Lowered to $145 at Jefferies
-
Increasing unusual put option volume: IBRX HSBC CRVS KBE HWM HBAN NUAI SEI COPX PSX ABT
-
Abbott (ABT) Reports In-Line Q4 EPS; offers guidance
-
Abbott (ABT) call put ratio 1 call to 1.7 puts into quarter results
-
Abbott (ABT) call put ratio 1 call to 1 put into quarter results
-
TD Cowen on Abbott Labs (ABT): 'We Expect A Good Q4 Report'
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
Abbott (ABT) call put ratio 2 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Abbott launches AI-powered meal guidance feature for diabetes app
-
Increasing unusual call option volume: FEZ ZSL TRIP UA NAVN SLS LCTX AXTI COMP RARE GGLL ABT
-
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
-
Bernstein Shares Takeaways From the 5th Annual Diabetes Disruptor Conference

